BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Small Cell Lung Cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
1238 results:

  • 1. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
    Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
    [No Abstract]    [Full Text] [Related]  

  • 2. Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer.
    Lv M; Li X; Yin Z; Yang H; Zhou B
    PLoS One; 2024; 19(4):e0294227. PubMed ID: 38564630
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.
    Bi YY; Chen Q; Yang MY; Xing L; Jiang HL
    Nat Commun; 2024 Mar; 15(1):2759. PubMed ID: 38553451
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Evolutionary trajectories of small cell lung cancer under therapy.
    George J; Maas L; Abedpour N; Cartolano M; Kaiser L; Fischer RN; Scheel AH; Weber JP; Hellmich M; Bosco G; Volz C; Mueller C; Dahmen I; John F; Alves CP; Werr L; Panse JP; Kirschner M; Engel-Riedel W; Jürgens J; Stoelben E; Brockmann M; Grau S; Sebastian M; Stratmann JA; Kern J; Hummel HD; Hegedüs B; Schuler M; Plönes T; Aigner C; Elter T; Toepelt K; Ko YD; Kurz S; Grohé C; Serke M; Höpker K; Hagmeyer L; Doerr F; Hekmath K; Strapatsas J; Kambartel KO; Chakupurakal G; Busch A; Bauernfeind FG; Griesinger F; Luers A; Dirks W; Wiewrodt R; Luecke A; Rodermann E; Diel A; Hagen V; Severin K; Ullrich RT; Reinhardt HC; Quaas A; Bogus M; Courts C; Nürnberg P; Becker K; Achter V; Büttner R; Wolf J; Peifer M; Thomas RK
    Nature; 2024 Mar; 627(8005):880-889. PubMed ID: 38480884
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Metformin and buparlisib synergistically induce apoptosis of non-small lung cancer (NSCLC) cells via Akt/FoxO3a/Puma axis.
    Shanshan W; Hongying M; Jingjing F; Rui Y
    Toxicol In Vitro; 2024 May; 97():105801. PubMed ID: 38479708
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
    Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
    Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Exploration of Ginkgo biloba leaves on non-small cell lung cancer based on network pharmacology and molecular docking.
    Wang M; Li R; Bai M; Zhou X
    Medicine (Baltimore); 2024 Mar; 103(9):e37218. PubMed ID: 38428907
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
    Zheng J; Wang T; Yang Y; Huang J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wang H; Cang S; Wu N; Song W; Liu X; Zhao S; Ding L; Selvaggi G; Wang Y; Xiao S; Wang Q; Shen Z; Zhou J; Zhou J; Zhang L
    Cancer Commun (Lond); 2024 Apr; 44(4):455-468. PubMed ID: 38421881
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small cell lung cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic treatment Evaluation.
    Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
    Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Next-Generation Sequencing in lung cancers-A Single-Center Experience in Taiwan.
    Lai WA; Huang YS; Chang KC; Yang SF; Yang CJ; Liu YW; Chen HD
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399524
    [No Abstract]    [Full Text] [Related]  

  • 11. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and tp53 mutant undifferentiated lung cancer.
    Chen J; Zheng Q; Wang J; Zhang X; Lv Y
    Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
    Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
    BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
    Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib.
    Yin A; Veerman GDM; van Hasselt JGC; Steendam CMJ; Dubbink HJ; Guchelaar HJ; Friberg LE; Dingemans AC; Mathijssen RHJ; Moes DJAR
    CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):612-623. PubMed ID: 38375997
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Exosome inhibition improves response to first-line therapy in small cell lung cancer.
    Irep N; Inci K; Tokgun PE; Tokgun O
    J Cell Mol Med; 2024 Feb; 28(4):e18138. PubMed ID: 38353469
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.
    Michels S; Massutí B; Vasyliv I; Stratmann J; Frank J; Adams A; Felip E; Grohé C; Rodriguez-Abreu D; Bischoff H; Carcereny I Costa E; Corral J; Pereira E; Fassunke J; Fischer RN; Insa A; Koleczko S; Nogova L; Reck M; Reutter T; Riedel R; Schaufler D; Scheffler M; Weisthoff M; Provencio M; Merkelbach-Bruse S; Hellmich M; Sebastian M; Büttner R; Persigehl T; Rosell R; Wolf J
    ESMO Open; 2024 Feb; 9(2):102237. PubMed ID: 38350336
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Influence of
    Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
    JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer.
    Lee K; Choi YJ; Lim HI; Cho KJ; Kang N; Ko SG
    BMC Complement Med Ther; 2024 Feb; 24(1):70. PubMed ID: 38303001
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
    Menzel M; Kirchner M; Kluck K; Ball M; Beck S; Allgäuer M; Assmann C; Schnorbach J; Volckmar AL; Tay TKY; Goldschmid H; Tan DS; Thomas M; Kazdal D; Budczies J; Stenzinger A; Christopoulos P
    J Pathol Clin Res; 2024 Mar; 10(2):e354. PubMed ID: 38284983
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer.
    Gu C; Wang X; Wang K; Xie F; Chen L; Ji H; Sun J
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272564
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 62.